Sunday November 22 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

4SC AG

4SC is a drug discovery and development company that uses its cheminformatics-based technology platform for the discovery and development of new drug candidates for the treatment of patients suffering from diseases with high medical needs.
Thus, 4SC has been generating a risk-balanced and continuously advancing pipeline of projects. 4SC's therapeutic focus centres on cancer and inflammatory diseases since these indications combine significant market potential and high medical needs with reasonable development time and cost in the early clinical stages.
4SC's most advanced drug candidate for the treatment of autoimmune disorders SC12267, has successfully completed phase I studies. Preparations for phase IIa trials with rheumatoid arthritis patients are under way. Additional programmes in research and pre-clinical stages are progressing towards clinical development. All of 4SC's pipeline projects have been generated by 4SC's proprietary technology platform.
4SC aims to realise the commercial potential of these programmes through licensing arrangements with pharmaceutical partners.


Contact Details:
Am Klopferspitz 19a
Martinsried
82152
Germany
Tel:49 (0)89 700763-0
Fax:49 (0)89 700763-29
Email:manfred.groeppel@4sc.com
WWW:

www.4sc.de/




Recent Publications by 4SC AG:

Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Toll-like receptor (TLR)-mediated signaling is proposed as an...
24th October, 2009
4SC AG, Martinsried, Germany. J Immunotoxicol. 2009 Oct 22.
DOI Direct Link
N-substituted 2'-(aminoaryl)benzothiazoles as kinase inhibitors: hit identification and scaffold hopping.
Starting with a hit from vHTS attained by a docking procedure of virtual...
29th August, 2009
4SC AG, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1349-56. Epub 2009 Jan 22.
DOI Direct Link
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
New structural classes of K(V)1.3 and IK-1 ion channel blockers have been...
27th August, 2009
4SC AG, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304. Epub 2009 Feb 25.
DOI Direct Link
Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization.
Based on an (aminoaryl)benzothiazole quinazoline hit structure for kinase...
21st August, 2009
4SC AG, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany. Bioorg Med Chem. 2009 Sep 15;17(18):6728-37. Epub 2009 Jul 25.
DOI Direct Link
Discovery of 5-HT6 receptor ligands based on virtual HTS.
Based on a pharmacophore alignment on a 5-HT(6) ligand applying 4SCan...
24th June, 2008
4SC AG, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6224-9. Epub 2007 Sep 8.
DOI Direct Link

View more 4SC AG research publications.

Press Releases on 4SC AG:

BioPortfolio Logo
SWITCH Biotech Selects 4SC as Partner for the Discovery and Development 1st April, 2002 Switch
SWITCH Biotech Selects 4SC as Partner for the Discovery and Development of Active Compounds for the Treatment of Psoriasis Neuried/Martinsried (October 13, 2003) - 4SC, a drug discovery

BioNews Results for 4SC AG:

::: 4SC Announces First Patient Treated in Phase IIb Rheumatoid Arthritis Study with 4SC-101
Biotech Intelligence:  Nov 9 2009 9:03AM Matching: 4sc ag
Enzyme Research: Reports from 4SC AG describe recent advances in enzyme research
NewsRX:  Oct 19 2009 8:50PM Matching: 4sc ag
Researchers test Orizon Research's ALKA-V6 silicon-based compound
News-Medical.Net:  Oct 14 2009 6:35AM Matching: 4sc ag
4SC begins phase II trial with 4SC-201 HDAC inhibitor in liver cancer patients
PharmaBiz:  Aug 20 2009 3:22PM Matching: 4sc ag

4SC AG Clinical Trials:

4SC-201 and Sorafenib in Advanced Hepatocellular Carcinoma

4SC AG Patents:

US Patent No.Title
7601745 Heterocyclic NF-kB inhibitors
6949567 Compounds for the treatment of protozoal diseases
7176241 Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
7247736 Method of identifying inhibitors of DHODH
7276606 Phenantridine analogues and uses thereof

View more 4SC AG patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 186 times since April 2007, the link to the organisation's website has been followed 29 times

Search for more companies in Martinsried

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for 4SC AG

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.